From the lab to the jab: How BioNTech-Pfizer won the vaccine race - News Summed Up

From the lab to the jab: How BioNTech-Pfizer won the vaccine race


Three-quarters of the more than 100 coronavirus inoculation trials across the world would end up using Schott products. The company alone aims to produce enough vials to hold two billion doses of a coronavirus vaccine by the end of 2021, head of communications Christina Rettig told AFP. And so planning had to begin for the unprecedented logistical challenge of transporting millions of life-saving vaccine doses worldwide. Binder in Tuttlingen has its “super freezers” which were already tapped as early as March to chill coronaviruses used in laboratory research by BioNTech and another German vaccine developer, CureVac. Edith Kwoizalla, 101 years old, became the first in Germany to receive the jab in the elderly home in Saxony-Anhalt state.


Source: Philippine Daily Inquirer December 26, 2020 21:56 UTC



Loading...
Loading...
  

Loading...

                           
/* -------------------------- overlay advertisemnt -------------------------- */